Intellectualization of Drug Development to Drive the Fragment-Based Drug Discovery Market, According to a Soon to be Released Report by Global Industry Analysts, Inc.

GIA announces the launch of a comprehensive primary research program studying the global market for “Fragment-Based Drug Discovery”. The soon to be released report identifies growing focus on drug lead optimization strategies and higher “hit” rates of FBDD, as key market driving forces.

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friendRepost This
Fragment-Based Drug Discovery: A Global Multi-Client Research Initiative

San Jose, California (PRWEB) October 11, 2013

Follow us on LinkedIn – GIA invites senior industry executives, domain experts, technologists and market strategists to participate in a comprehensive global research initiative studying the Fragment-Based Drug Discovery markets. The study will examine key drivers and trends impacting the market such as growing emphasis on successful lead discovery and optimization strategies by pharma companies to protect R&D investments; increase in the number of failures in late-stage clinical trials and the resulting shift in preference towards fragment-based drug discovery approach as against high-throughput screening (HTS) procedures; pressing need to accelerate drug discovery and development time; and technology advances and its positive impact on adoption by major pharmaceutical companies.

Defined as a process that constructs drug leads from small molecular fragments, fragment-based drug discovery (FBDD) is being widely touted as an effective alternative to traditional methods of lead generation in drug discovery. Key benefits of this drug discovery approach driving its adoption include ability to reliably generate potent molecules, cost effective as compared to high-throughput screening, higher number of superior quality drug candidates entering clinical trials and lower attrition rate of drug candidates in development, reduced risk of late-stage failures of clinical trials, shorter drug development time and faster time-to-market benefits. Over the years, a variety of fragment-based lead discovery techniques have been developed such as, X-ray crystallography, functional screening, mass spectrometry, in silico screening, and nuclear magnetic resonance (NMR). Future growth in the market will stem from rapid developments in highly sensitive screening platforms, advances in the field of fragment merging and linking, and innovation in approaches that optimize fragment exploitation.

A key commercial driver fuelling adoption among biotech companies is the increased focus on drug lead optimization strategies, given that early phases of lead optimization determine the success or failure of investment intensive drug discovery projects. The pharmaceutical research industry is steadily shifting from commoditization to intellectualization of the drug discovery process. This is mirrored in the steadily shrinking library size of research compounds. Over the years, proteomics, genomics, combinatorial chemistry and high-throughput screening (HTS), have generated massive volumes of information triggering industrialization of drug discovery. HTS especially played a key role in creating larger compound libraries which failed to yield desired results in drug research. The current move towards developing high-quality smart libraries and/or target focused compound libraries is bringing out fragment based drug discovery as the future of drug research and development.

The study estimates Fragment-Based Drug Discovery to be a multi-million dollar market worldwide, while more precise market-size and growth projections will be made available during the 2nd stage of report preparation, and data analysis.

The research and analyses will be released shortly in the form of a comprehensive research report. The report by design, will attempt to provide exhaustive analysis, data, trends, market share, market size, statistics, forecasts and competitive intelligence. The report is modeled to offer precise and unbiased, actionable market insights including in-depth segmentation of market sub-sectors, demand estimates and projections and analysis of trends in each of the sectors, identification of leading players, and the competitive structure, among others.

Developed for Drug Developers, Strategic Planners, Business Development Executives, Management Consultants, Investment Bankers, Consulting Firms, Marketing & Sales Executives, C-Level Decision Makers, Market Strategists and Technology Domain Experts, the report helps identify the biggest opportunities in this space and offers accurate latent demand forecasting that empowers quantitative decision making among existing market players and new entrants.

For more details about how you can participate, please click here.

About Global Industry Analysts, Inc.
Global Industry Analysts, Inc., (GIA) is a leading publisher of off-the-shelf market research. Founded in 1987, the company currently employs over 800 people worldwide. Annually, GIA publishes more than 1300 full-scale research reports and analyzes 40,000+ market and technology trends while monitoring more than 126,000 Companies worldwide. Serving over 9500 clients in 27 countries, GIA is recognized today, as one of the world's largest and reputed market research firms.

Follow us on LinkedIn.

Global Industry Analysts, Inc.
Telephone: 408-528-9966
Fax: 408-528-9977
Email: press(at)StrategyR(dot)com
Web Site: http://www.StrategyR.com/

###


Contact

Attachments